Cellgen Diagnostics

At Cellgen, we are developing a universal clinical trial ecosystem that allows life science companies to transform and automate their business processes into the cloud, while also achieving real-time interoperability and analytics of all data, documents, and processes.

Our mission is to make personalized cell therapy a reality for patients worldwide, providing accessible treatments to various unmet needs. Meet the people behind BioGenCell: A Group of Dedicated BioMed, Healthcare, Vascular and Business Professionals, Including a Nobel Prize Laureate and World-Renowned Scientists. BioGenCell is dedicated to changing the lives of patients suffering from degenerative microvascular diseases, stopping disease progression, reversing disability, reducing pain, and enhancing functionality. BioGenCell’s groundbreaking cell-therapy treatments aim to provide more accessible, reliable and cost-effective therapeutic options, with the hope of significantly impacting these tragic figures. BioGenCell’s Phase 2 Clinical Trial assesses the safety and efficacy of the BGC101 cell therapy in treating Chronic Limb-Threatening Ischemia. Since its inception in 2008, BioGenCell has been committed to transforming the lives of patients with degenerative diseases through advanced cell therapy treatments, based on the Company’s groundbreaking TRACT technology that uses a patient’s own blood as personalized medicine. Our innovative TRACT technology allows for stem cell therapies that are patient-friendly and physician-friendly. Through advanced, standardized procedures, we are dedicated to bringing transformative cell therapy treatments to vascular physicians and surgeons, podiatrists, and various other healthcare providers and clinicians.

Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as proprietary serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world. Sartorius CellGenix has more than two and a half decades of in-house expertise in GMP manufacturing and development of products (for dendritic cells, HSC, cord blood cells and chondrocytes) in the field of cell and gene therapy and regenerative medicine. Sartorius CellGenix’ current Quality Management (QM) system was established for manufacturing of recombinant protein investigational products (patient specific idiotype vaccines and recombinant tumor vaccines) in compliance with GMP under manufacturing authorization from German regulatory authorities. Our mission is to enable and accelerate safe and efficient transition of cell, gene and tissue engineered products from preclinical to post-approval clinical applications for the benefit of patients worldwide. Before joining CellGenix Daniel was responsible as CBO for the global sales and marketing organization at PromoCell GmbH, a premier manufacturer for primary cells and media. Ori Biotech and Sartorius CellGenix collaborate in order to promote innovation within closed-system, cell and gene therapy manufacturing.

Caligenix is a new kind of diagnostic company — existing at the intersection of machine learning, cellular engineering, and supplementation recommendation — pioneering Diagnostic Biology™ to create breakthrough personalization. Having built the first-of-its-kind DNA + RNA biomarker test, a fully automated globally recognized robotics lab and the artificial intelligence (AI) to generate personalized recommendations, Caligenix is empowering the world’s best wellness product brands with the evidence, feedback loop and genomic expression they have long needed to improve the health and lives of their customers.

We are a privately held company with headquarter in Irvine, California and access to 30,000 sq. Currently, we are in clinical stage of developing several unique chimeric antigen receptor (CAR) T cell and natural killer cell-based therapeutics for advanced hematopoietic cancers and solid tumors. The location of our operations provides us with many potential strategic advantages, including proximity to world’s largest pharmaceutical market and access to largest number of patients. We leverage this high-efficient and versatile cellular processing and manufacturing platform to develop a robust pipeline of cell and gene therapy products for the treatment of cancers and rare genetic disorders. In-depth and extensive experiences in leading molecular & cell biology, cancer biology and cell therapeutic studies.

At Celligenics, we are reinventing the way forward by harnessing regenerative technology to support the body in repairing, regenerating, and restoring itself to a state of well-being. Established in 2016, Celligenics is a spin-off of the Agency for Science, Technology & Research (A*STAR), Singapore’s leading public R&D agency, and one of A*STAR’s top 10 new biotech start-ups in 2018. We are also a finalist for Singapore’s Emerging Enterprise Award 2021, the top business award jointly organised by OCBC Bank and The Business times that recognises the ambitions of emerging enterprises. Celligenics Announces China Market Entry, & Signs MOU With West China Hospital. Celligenics, NTU, & SRIS Collaborate On New Therapy For Chronic Wounds (Sep 2021). Our regenerative extract is a platform technology, with limitless application potential. Two product lines are currently under development, with more to come. Traditional skincare products lose their effectiveness over time, and stronger and more expensive products are then required to maintain the health of our skin.